{"id":27409,"date":"2024-12-19T04:29:00","date_gmt":"2024-12-18T20:29:00","guid":{"rendered":"http:\/\/csccm.org.cn\/?p=27409"},"modified":"2024-12-19T05:54:35","modified_gmt":"2024-12-18T21:54:35","slug":"jama%e5%8f%91%e8%a1%a8%e8%ae%ba%e6%96%87%ef%bc%9a%e6%80%a5%e6%80%a7%e5%91%bc%e5%90%b8%e5%8a%9f%e8%83%bd%e8%a1%b0%e7%ab%ad%e6%82%a3%e8%80%85%e7%9a%84%e9%ab%98%e6%b5%81%e9%87%8f%e9%bc%bb%e5%af%bc","status":"publish","type":"post","link":"https:\/\/csccm.org.cn\/?p=27409","title":{"rendered":"[JAMA\u53d1\u8868\u8bba\u6587]\uff1a\u6025\u6027\u547c\u5438\u529f\u80fd\u8870\u7aed\u60a3\u8005\u7684\u9ad8\u6d41\u91cf\u9f3b\u5bfc\u7ba1\u6c27\u7597\u4e0e\u65e0\u521b\u673a\u68b0\u901a\u6c14"},"content":{"rendered":"\n

Original Investigation <\/p>\n\n\n\n

Caring for the Critically Ill Patient<\/p>\n\n\n\n

December 10, 2024<\/p>\n\n\n\n

High-Flow Nasal Oxygen vs Noninvasive Ventilation in Patients With Acute Respiratory Failure: The RENOVATE Randomized Clinical Trial<\/h1>\n\n\n\n

RENOVATE Investigators and the BRICNet Authors<\/h3>\n\n\n\n

JAMA.\u00a0<\/em>Published online December 10, 2024. doi:10.1001\/jama.2024.26244<\/p>\n\n\n\n

Key Points<\/p>\n\n\n\n

Question<\/strong>  Is high-flow nasal oxygen noninferior to noninvasive ventilation for rate of endotracheal intubation or death at 7 days in patients with acute respiratory failure due to a variety of causes?<\/p>\n\n\n\n

Findings<\/strong>  In this randomized clinical trial (n\u2009=\u20091766 patients), a bayesian hierarchical model with dynamic borrowing across 5 patient groups found high-flow nasal oxygen was noninferior (defined by a posterior probability \u22650.992 for an odds ratio <1.55) to noninvasive ventilation for rates of endotracheal intubation or death at 7 days in 4 of the patient groups (nonimmunocompromised with hypoxemic acute respiratory failure, chronic obstructive pulmonary disease exacerbation with respiratory acidosis, acute cardiogenic pulmonary edema, and hypoxemic COVID-19). One patient group (immunocompromised with hypoxemic acute respiratory failure) was stopped for futility.<\/p>\n\n\n\n

Meaning<\/strong>  Compared with noninvasive ventilation, high-flow nasal oxygen met prespecified criteria for noninferiority for the outcome of endotracheal intubation or death within 7 days in 4 of the 5 patient groups with acute respiratory failure.<\/a><\/p>\n\n\n\n

Abstract<\/p>\n\n\n\n

Importance<\/strong>  High-flow nasal oxygen (HFNO) and noninvasive ventilation (NIV) are commonly used respiratory support therapies for patients with acute respiratory failure (ARF).<\/p>\n\n\n\n

Objective<\/strong>  To assess whether HFNO is noninferior to NIV on the rates of endotracheal intubation or death at 7 days in 5 patient groups with ARF.<\/p>\n\n\n\n

Design, Setting, and Participants<\/strong>  This noninferiority, randomized clinical trial enrolled hospitalized adults (aged \u226518 years; classified as 5 patient groups with ARF: nonimmunocompromised with hypoxemia, immunocompromised with hypoxemia, chronic obstructive pulmonary disease [COPD] exacerbation with respiratory acidosis, acute cardiogenic pulmonary edema [ACPE], or hypoxemic COVID-19, which was added as a separate group on June 26, 2023) at 33 hospitals in Brazil between November 2019 and November 2023 (final follow-up: April 26, 2024).<\/p>\n\n\n\n

Interventions<\/strong>  High-flow nasal oxygen (n\u2009=\u2009883) or NIV (n\u2009=\u2009883).<\/p>\n\n\n\n

Main Outcomes and Measures<\/strong>  The primary outcome was endotracheal intubation or death within 7 days assessed using a bayesian hierarchical model with dynamic borrowing across patient groups. Noninferiority was defined by a posterior probability of 0.992 or greater for an odds ratio (OR) less than 1.55.<\/p>\n\n\n\n

Results<\/strong>\u00a0\u00a0Among 1800 patients, 1766 completed the study (mean age, 64 [SD, 17] years; 707 [40%] were women). The primary outcome of endotracheal intubation or death at 7 days occurred in 39% (344\/883) in the HFNO group vs 38% (336\/883) in the NIV group. In the immunocompromised with hypoxemia patient group, the primary outcome occurred in 57.1% (16\/28) in the HFNO group vs 36.4% (8\/22) in the NIV group; enrollment was stopped for futility (final OR, 1.07; 95% credible interval [CrI], 0.81-1.39; noninferiority posterior probability [NPP], 0.989). In the nonimmunocompromised with hypoxemia group, the primary outcome occurred in 32.5% (81\/249) in the HFNO group vs 33.1% (78\/236) in the NIV group (OR, 1.02 [95% CrI, 0.81-1.26]; NPP, 0.999). In the ACPE group, the primary outcome occurred in 10.3% (14\/136) in the HFNO group vs 21.3% (29\/136) in the NIV group (OR, 0.97 [95% CrI, 0.73-1.23]; NPP, 0.997). In the hypoxemic COVID-19 group, the primary outcome occurred in 51.3% (223\/435) in the HFNO group vs 47.0% (210\/447) in the NIV group (OR, 1.13 [95% CrI, 0.94-1.38]; NPP, 0.997). In the COPD exacerbation with respiratory acidosis group, the primary outcome occurred in 28.6% (10\/35) in the HFNO group vs 26.2% (11\/42) in the NIV group (OR, 1.05 [95% CrI, 0.79-1.36]; NPP, 0.992). However, a post hoc analysis without dynamic borrowing across the 5 ARF patient groups revealed some qualitatively different results in patients with COPD, immunocompromised patients, and patients with ACPE. The incidence of serious adverse events was similar (9.4% of patients in HFNO group vs 9.9% in NIV group).<\/p>\n\n\n\n

\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n

Conclusions and Relevance<\/strong>  Compared with NIV, HFNO met prespecified criteria for noninferiority for the primary outcome of endotracheal intubation or death within 7 days in 4 of the 5 patient groups with ARF. However, the small sample sizes in some patient groups and the sensitivity of the findings to the choice of analysis model suggests the need for further study in patients with COPD, immunocompromised patients, and patients with ACPE.<\/p>\n\n\n\n

Trial Registration<\/strong>  ClinicalTrials.gov Identifier: NCT03643939<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Original Investigation  Caring for the Critically […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[32,23],"tags":[],"_links":{"self":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/27409"}],"collection":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=27409"}],"version-history":[{"count":1,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/27409\/revisions"}],"predecessor-version":[{"id":27410,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/27409\/revisions\/27410"}],"wp:attachment":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=27409"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=27409"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=27409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}